0.92
-0.0033(-0.36%)
Currency In USD
| Previous Close | 0.92 |
| Open | 0.91 |
| Day High | 0.95 |
| Day Low | 0.91 |
| 52-Week High | 2.35 |
| 52-Week Low | 0.27 |
| Volume | 22,412 |
| Average Volume | 1.42M |
| Market Cap | 32.7M |
| PE | -1.62 |
| EPS | -0.57 |
| Moving Average 50 Days | 1.45 |
| Moving Average 200 Days | 0.83 |
| Change | -0 |
If you invested $1000 in Equillium, Inc. (EQ) since IPO date, it would be worth $65.76 as of November 13, 2025 at a share price of $0.921. Whereas If you bought $1000 worth of Equillium, Inc. (EQ) shares 5 years ago, it would be worth $203.25 as of November 13, 2025 at a share price of $0.921.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Equillium to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory diso
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 03, 2025 9:05 PM GMT
LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on October 31, 2025, the Compensation
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
GlobeNewswire Inc.
Oct 22, 2025 12:00 PM GMT
Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitisLA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nas